Adaptam Therapeutics, a San Sebastián- and Barcelona-based biotech company developing cancer immunotherapies that target immunosuppressive myeloid cells, has secured €3 million in a pre-seed financing round led by Criteria Bio Ventures, as Vestbee was informed.
- Established in 2025 by Asis Palazon, Adaptam Therapeutics is a biotech spin-off from CIC bioGUNE in Spain developing next-generation cancer immunotherapies.
- The company focuses on targeting immunosuppressive myeloid cells in the tumor microenvironment, which can prevent immune cells from effectively attacking solid tumors.
- Adaptam is developing first-in-class antibody-based therapies, including antibody-drug conjugates (ADCs) and bispecific antibodies, directed at novel glyco-immune checkpoints expressed in these myeloid cells.
- By modulating the immunosuppressive tumor environment, the company aims to improve the effectiveness of cancer immunotherapies in patients who do not respond to existing treatments.
Details of the deal
- The round was led by Criteria Bio Ventures, a life sciences venture fund investing in biotech companies developing therapies for unmet medical needs, primarily in Europe. Its representatives, Salvatore Cappadona, PhD, and Pablo Cironi, PhD, have joined Adaptam’s board of directors.
- With the fresh capital raised, the firm plans to advance its first-in-class antibody-based therapeutic programs, including antibody-drug conjugates (ADCs) and bispecific antibodies, into preclinical development across multiple oncology indications.
- The funding will also support the expansion of Adaptam’s scientific and operational capabilities as it prepares for its next financing round to enable IND-enabling studies.
"The support from Criteria Bio Ventures enables us to take a step forward in achieving our mission. We are now actively planning our next funding round to support IND-enabling studies," claims Asis Palazon, PhD, founder, CEO and CSO of Adaptam.
